Delivery Order SPE2DB24D3013-SPE2DB25FFNVC
Award Date 7/29/25
Potential Completion Date 7/30/25
Potential Value $7.5K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,621.24 for Zepbound 5 mg/0.5 mL pens on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, representing the...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,332.51 on August 13, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens. This competitively awarded, firm fixed-price delivery order is non-set-aside and is scheduled for completion by August 14, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management,...
- The Defense Logistics Agency awarded a delivery order valued at approximately $43.3K to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $33,127.32 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors. This non-set-aside competitive award is scheduled for completion by August 20, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication indicated for weight management, reflecting the federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $233,777.40 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designations and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist medication used in diabetes and...
- The Defense Logistics Agency awarded a delivery order valued at $42,562.60 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on July 30, 2025, with completion targeted for July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, reflecting the federal government's...
- The Defense Logistics Agency awarded a delivery order valued at $2,446.62 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pens on July 30, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and carries an ultimate completion date of July 31, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a recently approved diabetes and weight management...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $9,532.33 on August 27, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pens. This firm fixed-price, competitively awarded contract is set to be completed by August 28, 2025, and will be performed at the awardee's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management and diabetes treatment, reflecting the federal government's pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $8,624.79 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 mL pens on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitive, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist medication used in diabetes and weight management...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,232.80 on September 10, 2025, for the supply of Zepbound (tirzepatide) 12.5 mg/0.5 mL in pre-filled pen format. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...